Clinical Theranostic Specialist

We are seeking a Clinical Theranostic Specialist to serve as a senior field-based clinical and technical expert supporting approved and investigational radiopharmaceutical products. In this role, you will advance clinical adoption, institutional readiness, and workflow optimization across imaging and treatment centers. You will also partner cross-functionally with Medical Affairs, Clinical Development, Clinical Operations, and Commercial teams to translate scientific innovation into safe, compliant, and scalable real-world practice., * Build and sustain strategic relationships with KOLs and institutional stakeholders, including Nuclear Medicine Physicians, Radiologists, Radiation Oncologists, Technologists, Radiation Safety Officers, Health Physicists, Nursing Staff, and Advanced Practice Providers.

• Lead site readiness and workflow integration efforts for approved agents and clinical trials, including product handling, administration, radiation safety, and radiopharmaceutical licensing considerations.
• Deliver high-impact clinical and technical education to ensure safe, effective, and guideline-aligned product utilization.
• Serve as a senior subject matter expert in nuclear medicine and radiopharmaceutical applications, maintaining deep expertise in imaging techniques, oncology practice patterns, and emerging therapeutic advances.
• Support clinical trial execution through site training, protocol education, and alignment with Clinical Development and Operations.
• Respond to unsolicited scientific inquiries regarding approved and investigational products, ensuring accurate documentation and full regulatory compliance.
• Generate actionable field insights on diagnostic imaging and radiopharmaceutical trends, institutional barriers, and adoption dynamics, informing launch strategy.
• Provide medical and scientific congress support as requested, in compliance with company policies and industry regulations.
• Ensure adherence to all SOPs and regulatory frameworks, including U.S. Compliance Code of Conduct, OIG Guidance, PhRMA Code, GCP, HIPAA, and applicable FDA regulations.
• Applies AI to improve team execution and decision-making

• Bachelor’s degree required. (CNMT preferred)
• 7+ years of experience in nuclear medicine, radiopharmaceutical clinical applications, oncology imaging, or related field.
• Demonstrated experience leading complex site education and workflow implementation initiatives.
• Advanced understanding of radiopharmaceutical science, nuclear medicine operations, and diagnostic imaging trends.
• Ability to translate complex data into practical, site-level execution strategies.
• Strong executive presence and ability to build institutional relationships.
• Experience working cross-functionally within a matrixed biotech or pharmaceutical environment.
• Excellent communication, presentation, and organizational skills.
• Experience in oncology and radiopharmaceuticals is strongly preferred., BMS and RayzeBio will consider qualified applicants with arrest and conviction records, pursuant to applicable laws in your area.

Subject to the terms and conditions of the applicable plans then in effect, you may be eligible to participate in our comprehensive benefit plans - including wellbeing support, retirement and financial protection benefits, and insurance offerings (medical, dental, vision, life and disability).

U.S.-based exempt employees are eligible for Flexible Time Off (FTO), which provides paid time off without a set accrual limit, subject to manager approval, along with 11 paid company holidays each year.

Non-exempt employees, RayzeBio employees, and employees located in Puerto Rico receive 160 hours of paid vacation annually for new hires (subject to manager approval), 11 paid company holidays, and 3 optional holidays.

Depending on eligibility, employees may also have access to additional time-off benefits, including paid sick leave, up to two paid volunteer days per year, summer hours flexibility, and leaves of absence for medical, personal, parental, caregiver, bereavement, or military needs. Eligible employees also enjoy an annual Global Shutdown between Christmas Day and New Year’s Day.

U.S.-based job seekers can explore full benefit offerings at https://careers.bms.com/benefits

RayzeBio and Bristol Myers Squibb

RayzeBio was acquired by Bristol Myers Squibb (BMS) in 2024 and is a wholly-owned subsidiary of BMS; however, RayzeBio will continue to operate as a standalone organization.

At RayzeBio, every day is an opportunity to ignite meaningful change. As a wholly-owned subsidiary of Bristol Myers Squibb, RayzeBio blends the nimble, pioneering spirit of an emergent biotech with the global expertise and resources of a leading innovator in oncology. Our mission is to develop transformative radiopharmaceutical therapies that offer new hope for patients living with cancer. Here, you’ll join a multidisciplinary team where your ideas are valued, your expertise is amplified, and collaboration is at the heart of everything we do. From day one, expect to make an immediate impact-on our science, on our teams, and most importantly, on patients. Learn more about RayzeBio: https://careers.bms.com/rayzebio/

RayzeBio, a Bristol Myers Squibb company, is a dynamic biotechnology company headquartered in San Diego, CA. The company is focused on improving survival of people with cancer by harnessing the power of targeted radioisotopes. RayzeBio is developing innovative drugs against targets of solid tumors. Led by a successful and experienced entrepreneurial team, RayzeBio aims to be the global leader in radiopharmaceuticals

You will join a multidisciplinary team that values your ideas, strengthens your expertise, and puts collaboration at the center of our work. From day one, you can make an immediate impact on our science, our teams, and, most importantly, patients. Learn more about RayzeBio: https://careers.bms.com/rayzebio/

RayzeBio, a Bristol Myers Squibb company headquartered in San Diego, California, is a biotechnology company focused on improving cancer survival through targeted radioisotopes. The company is developing innovative therapies for solid tumor targets and aims to become a global leader in radiopharmaceuticals.